ArticleJournal, genetic engineering & biotechnology2026
Prevalence and antibiotic resistance pattern of Staphylococcus spp. isolated from acne, and disrupting their antimicrobial resistance: unveiling the potential of Ganoderma lucidum extract.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Computational identification and characterization of high-risk human KRAS nsSNPs: Impacting structure, ligand binding, and cancer prognosis.Journal, genetic engineering & biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus (S. aureus) and Staphylococcus epidermidis (S. epidermidis) are major skin commensals involved in acne pathogenesis and are increasingly associated with antibiotic resistance. This study aimed to determine the prevalence and resistance patterns of isolated Staphylococcus spp., identify associated risk factors, and evaluate the antibacterial activity of Ganoderma lucidum (G. lucidum) extract as a potential natural therapeutic alternative. Acne lesion samples from 135 volunteers were analyzed, yielding 128 S. aureus and 135 S. epidermidis isolates confirmed by biochemical tests. Antibiotic susceptibility was assessed against commonly used drugs. The antibacterial efficacy of G. lucidum extract was tested on Mueller-Hinton agar. Bioinformatics analysis, including molecular docking and ADMET profiling, predicted interactions of G. lucidum bioactives with resistance-related proteins (ermC, mecA, and β-lactamase). Gentamicin and rifampin showed 100% susceptibility in both species. However, erythromycin resistance was 93.3% in S. aureus and 60% in S. epidermidis, while amoxicillin resistance was highest in S. epidermidis (86.7%). Significant risk factors included age, gender, BMI, oily skin, family history, diet, and psychological stress. G. lucidum extract exhibited strong dose-dependent antibacterial activity against both species. Docking and dynamic simulations revealed lucidenic acid D1 strongly and stably binding ermC, while ganoderlactone B and E showed dual binding to mecA and β-lactamase, suggesting inhibition of erythromycin and amoxicillin resistance. ADMET analysis confirmed favorable pharmacokinetics and low toxicity. The study highlights high prevalence of antibiotic-resistant staphylococci in acne and demonstrates the potential of G. lucidum as an effective natural antibacterial and resistance-modifying agent, offering a promising alternative to conventional antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.